Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Upregulation of GRIM-19 augments the sensitivity of prostate cancer cells to docetaxel by targeting Rad23b.

Lin H, Shen Z, Liu H, Yang M, Lin J, Luo L, Liu L, Chen H.

Clin Exp Pharmacol Physiol. 2019 Sep 17. doi: 10.1111/1440-1681.13179. [Epub ahead of print]

PMID:
31531888
2.

Inhibition of miR-423-5p suppressed prostate cancer through targeting GRIM-19.

Lin H, Lin T, Lin J, Yang M, Shen Z, Liu H, Zou Z, Zheng Z.

Gene. 2019 Mar 10;688:93-97. doi: 10.1016/j.gene.2018.11.021. Epub 2018 Nov 8.

PMID:
30415005
3.

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L.

Mol Cancer. 2016 Nov 10;15(1):70.

4.

microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.

Gao Q, Zheng J.

Biomed Pharmacother. 2018 Jan;97:528-534. doi: 10.1016/j.biopha.2017.10.040. Epub 2017 Nov 6.

PMID:
29091904
5.

Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.

Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN.

Cancer Biol Ther. 2011 Jan 15;11(2):204-12. Epub 2011 Jan 15.

6.

Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.

Yang Z, Chen JS, Wen JK, Gao HT, Zheng B, Qu CB, Liu KL, Zhang ML, Gu JF, Li JD, Zhang YP, Li W, Wang XL, Zhang Y.

J Exp Clin Cancer Res. 2017 Dec 8;36(1):178. doi: 10.1186/s13046-017-0649-3.

7.

siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells.

Razi Soofiyani S, Mohammad Hoseini A, Mohammadi A, Khaze Shahgoli V, Baradaran B, Hejazi MS.

Adv Pharm Bull. 2017 Dec;7(4):637-643. doi: 10.15171/apb.2017.076. Epub 2017 Dec 31.

8.

Overexpression of GRIM-19 accelerates radiation-induced osteosarcoma cells apoptosis by p53 stabilization.

Chen W, Liu Q, Fu B, Liu K, Jiang W.

Life Sci. 2018 Sep 1;208:232-238. doi: 10.1016/j.lfs.2018.07.015. Epub 2018 Jul 10.

PMID:
30005830
9.

Subcellular distribution of RAD23B controls XPC degradation and DNA damage repair in response to chemotherapy drugs.

You X, Guo W, Wang L, Hou Y, Zhang H, Pan Y, Han R, Huang M, Liao L, Chen Y.

Cell Signal. 2017 Aug;36:108-116. doi: 10.1016/j.cellsig.2017.04.023. Epub 2017 May 1.

PMID:
28473198
10.

[Expression of AXL enhances docetaxel-resistance of prostate cancer cells].

Lin JZ, Zhu JG, Wu HF, Li JM, DE W, Wang ZJ.

Zhonghua Nan Ke Xue. 2017 Apr;23(4):302-308. Chinese.

PMID:
29714413
11.

Expression of GRIM-19 in unexplained recurrent spontaneous abortion and possible pathogenesis.

Yang Y, Cheng L, Deng X, Yu H, Chao L.

Mol Hum Reprod. 2018 Jul 1;24(7):366-374. doi: 10.1093/molehr/gay020.

PMID:
29741731
12.

EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).

Hour TC, Chung SD, Kang WY, Lin YC, Chuang SJ, Huang AM, Wu WJ, Huang SP, Huang CY, Pu YS.

Arch Toxicol. 2015 Apr;89(4):591-605. doi: 10.1007/s00204-014-1275-x. Epub 2014 Jun 3.

PMID:
24888374
13.

Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.

Gan L, Wang J, Xu H, Yang X.

Prostate. 2011 Aug 1;71(11):1158-66. doi: 10.1002/pros.21331. Epub 2011 Jan 12.

PMID:
21656826
14.

siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells.

Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY.

Asian Pac J Cancer Prev. 2012;13(6):2485-9.

15.
16.

The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.

Lundon DJ, Boland A, Prencipe M, Hurley G, O'Neill A, Kay E, Aherne ST, Doolan P, Madden SF, Clynes M, Morrissey C, Fitzpatrick JM, Watson RW.

BMC Cancer. 2017 Mar 1;17(1):163. doi: 10.1186/s12885-017-3100-4.

17.

Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.

Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, Kanimoto Y, Ehara H, Ito H, Seishima M, Deguchi T, Ito M.

Urol Oncol. 2015 Sep;33(9):385.e15-20. doi: 10.1016/j.urolonc.2015.04.019. Epub 2015 May 28.

PMID:
26027763
18.

Functional p53 determines docetaxel sensitivity in prostate cancer cells.

Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC.

Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19.

19.

Regulation of Docetaxel Sensitivity in Prostate Cancer Cells by hsa-miR-125a-3p via Modulation of Metastasis-Associated Protein 1 Signaling.

Liu JZ, Yin FY, Yan CY, Wang H, Luo XH.

Urology. 2017 Jul;105:208.e11-208.e17. doi: 10.1016/j.urology.2017.01.001. Epub 2017 Jan 11.

PMID:
28088556
20.

Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel.

Gao W, Lin S, Cheng C, Zhu A, Hu Y, Shi Z, Zhang X, Hong Z.

Arch Biochem Biophys. 2019 Apr 15;665:69-78. doi: 10.1016/j.abb.2018.01.013. Epub 2018 Jan 31.

PMID:
29373811

Supplemental Content

Support Center